TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15762203
Drug: Self-warming lidocaine/tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-warming lidocaine/tetracaine patch
Study: 7031184
Drug: Phenylethylmalonamide 400
Normalized name: Phenylethylmalonylurea
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylethylmalonamide 400 mg daily for one week
Study: 7031184
Drug: Phenylethylmalonamide 800
Normalized name: Phenylethylmalonylurea
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylethylmalonamide 800 mg daily for a second week
Study: 3083705
Drug: Oral neomycin
Normalized name: neomycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral neomycin and erythromycin
Study: 31023274
Drug: Circadian Reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circadian Reinforcement Therapy (CRT) combined with electronic self-monitoring (Monsenso Daybuilder System)
Study: 20642710
Drug: Statins (atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (atorvastatin 10 mg, atorvastatin 80 mg, pravastatin 40 mg/day)
Study: 16131799
Drug: ZK 200775
Normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 200775 (525 mg in 48 h)
Study: 16131799
Drug: ZK 200775
Normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 200775 (105 mg over 6 h)
Study: 10628893
Drug: INN 00835
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INN 00835 (0.2 mg/kg, subcutaneously, once daily for 5 days)
Study: 10628893
Drug: Placebo (subcutaneously,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneously, once daily for 5 days)
Study: 384241
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (10 g per day)
Study: 26338890
Drug: Cocoa beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa beverage (960 mg total polyphenols; 480 mg flavanols)
Study: 26338890
Drug: Flavanol-free placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanol-free placebo (110 mg total polyphenols; <0.1 mg flavanols)
Study: 23670706
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (n=28)
Study: 23670706
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no lithium treatment, n=32)
Study: 18976879
Drug: Self-weighing at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-weighing at least weekly
Study: 15364747
Drug: IV amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV amiodarone (0.73 mg/min for 48 hours) followed by oral amiodarone (400 mg q12h for 3 days)
Study: 10743904
Drug: Commonly prescribed
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commonly prescribed analgesic medications
Study: 10743904
Drug: Participant-rated measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant-rated measures of drug liking and mood
Study: 8245113
Drug: Home-based burn
Normalized name: Burn Jel Plus
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home-based burn treatment modality
Study: 29615049
Drug: SB010 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB010 (10 mg bid for 28 days)
Study: 24197517
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser at low dose (30 mW, 10 J/cm², 9 s per point, 810 nm)
Study: 24197517
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser at high dose (100 mW, 90 J/cm², 11 s per point, 810 nm)
Study: 24197517
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser at low dose + Gluma Desensitizer
Study: 24197517
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser at high dose + Gluma Desensitizer
Study: 21568831
Drug: Handling strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handling strategies + specific strength exercises + weekly physiotherapist training
Study: 19309586
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy group (methylprednisolone, cyclophosphamide, Etanercept)
Study: 26786575
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy group
Study: 19309586
Drug: Normal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal therapy group
Study: 9526601
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml normal saline (N/S group)
Study: 9526601
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg tenoxicam (T group)
Study: 1286128
Drug: TTPG 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTPG 180 mg
Study: 1286128
Drug: TTPG 540
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTPG 540 mg
Study: 1286128
Drug: TTPG 1080
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTPG 1080 mg
Study: 1286128
Drug: TCA 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCA 180 mg
Study: 1286128
Drug: TCA 540
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCA 540 mg
Study: 1286128
Drug: TCA 1080
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCA 1080 mg
Study: 1286128
Drug: tiopronin 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiopronin 180 mg
Study: 1286128
Drug: tiopronin 540
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiopronin 540 mg
Study: 1286128
Drug: tiopronin 1080
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiopronin 1080 mg
Study: 16912706
Drug: Control (current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (current immunosuppressive treatment)
Study: 10951338
Drug: Gemcitabine 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1250 mg/m² and vinorelbine 25 mg/m² administered on Days 1 and 8 every 3 weeks for up to 9 courses
Study: 7941897
Drug: Adjuvant intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intramuscular immunoglobulin against tick‐borne encephalitis
Study: 7941897
Drug: Nonspecific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific treatment alone
Study: 2895840
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg twice a day
Study: 2895840
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg four times a day
Study: 2895840
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg once a day
Study: 2895840
Drug: After stopping
Approvals — FDA: no, EMA: no, PMDA: no
Description: After stopping treatment
Study: 28666335
Drug: Ginger 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger 160 mg/day
Study: 7725886
Drug: Ropivacaine 2.5
Normalized name: fentanyl-ropivacaine 2.5 mcg/mL-0.1%-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2.5 mg/ml
Study: 9773132
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg/ml
Study: 8582131
Drug: Metformin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2 x 850 mg day-1 for 2 days and 850 mg 1 h before evaluation)
Study: 645073
Drug: Dipyrone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (20 mg per kg body weight i.v.)
Study: 23053764
Drug: Ultra-short-course chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-short-course chemotherapy (2SHRZ/XHRZ) for an average duration of 4.5 months
Study: 23053764
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy for an average duration of 9 months
Study: 23053764
Drug: Ultra-short-course chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-short-course chemotherapy
Study: 19489966
Drug: Metvix cream
Normalized name: Metvixia
DrugBank: Methyl aminolevulinate (DB00992)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metvix cream
Study: 16728551
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (200 mg i.m. every 2 weeks for 3 months)
Study: 15327915
Drug: Regular cola
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular cola (710 ml, 24 oz)
Study: 15327915
Drug: Fat-free raspberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-free raspberry cookies (87 g, 3 oz)
Study: 10938022
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (3.0 g eicosapentaenoic acid/docosahexaenoic acid per day)
Study: 3313686
Drug: Diltiazem (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.3 mg/kg intravenously)
Study: 30038151
Drug: Oral valproic
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral valproic acid (VPA) 500 mg once a day for 3 months
Study: 30038151
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group continued on glaucoma therapy (n = 33 eyes)
Study: 26945271
Drug: Tolterodine (Detrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine (Detrol LA) extended release daily for 12 weeks
Study: 26945271
Drug: Intravaginal estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal estradiol cream (Estrace) nightly for 6 weeks then twice per week for 12 weeks
Study: 26945271
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (intravaginal estradiol + tolterodine) at 24 weeks
Study: 26945271
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (intravaginal estradiol + tolterodine) at 52 weeks
Study: 22918855
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of zolmitriptan 5 mg orodispersible tablet
Study: 22918855
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of zolmitriptan 5 mg orodispersible tablet
Study: 18487744
Drug: Computer-based scoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based scoring tool (tablet PC with standalone scoring application for TISS, SAPS2, and Apache 2)
Study: 15787917
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg x kg(‐1) orally, 30 min before surgery)
Study: 12853806
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation (ES) for 15 minutes twice daily
Study: 12853806
Drug: Biofeedback (BFB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback (BFB) for 15 minutes twice daily
Study: 10391261
Drug: TMR surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMR surgery and medication
Study: 1323943
Drug: Acyclovir, 800
Normalized name: Acyclovir, 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, 800 mg orally five times per day for 7 days
Study: 29957401
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) adjuvant therapy to the long down regulation protocol
Study: 23026181
Drug: Nasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal steroid (mometasone furoate nasal spray)
Study: 23026181
Drug: Antihistamine (fexofenadine)
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine (fexofenadine)
Study: 15292338
Drug: Estrogen (Ovcon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (Ovcon 35, 35 microg ethinyl estradiol, and 0.4 mg norethindrone)
Study: 15292338
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IGF-I (30 microg/kg sc twice a day)
Study: 15292338
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Estrogen and rhIGF-I
Study: 15292338
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rhIGF-I and E
Study: 11853331
Drug: Hyperimmune bovine
Normalized name: Cryptosporidium hyperimmune bovine colostrum IgG
DrugBank: Cryptosporidium immune globulin (DB17785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperimmune bovine colostrum (HBC) 100 ml three times a day for 3 days
Study: 11853331
Drug: HBC and
Normalized name: Aminosyn-HBC 7 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBC and BC with pivmecillinam 50 mg kg(‐1) d(‐1) for 5 days
Study: 7868973
Drug: LDL-apheresis without
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-apheresis without statin therapy
Study: 7868973
Drug: LDL-apheresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-apheresis with statin therapy (lovastatin or pravastatin)
Study: 3364227
Drug: Group Behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Behavioral Marital Therapy (BMT)
Study: 3364227
Drug: Interactional Marital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactional Marital Therapy
Study: 24815298
Drug: Probiotic (Symprove)
Normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Symprove) 1 mL/kg/day for 12 weeks
Study: 15721727
Drug: Cisatracurium (CIS)
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisatracurium (CIS) 0.10 mg/kg
Study: 15721727
Drug: Rocuronium (ROC)
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium (ROC) 0.60 mg/kg
Study: 12824971
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of ampicillin-sulbactam (3 g intravenously every 6 hours)
Study: 12824971
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of ampicillin-sulbactam (3 g intravenously every 6 hours)
Study: 1495748
Drug: IL-2 (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 (9 x 10(6) IU/m2, subcutaneously, twice daily for 3 days before surgery)
Study: 29688200
Drug: Standard comprehensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard comprehensive conservative treatment
Study: 16187469
Drug: Oral nonsteroidal
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nonsteroidal antiinflammatory drugs (NSAIDs)
Study: 16187469
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (diclofenac-paracetamol)
Study: 16187469
Drug: Diclofenac-paracetamol combination
Normalized name: diclofenac, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac-paracetamol combination
Study: 16187469
Drug: All combinations
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All combinations (NSAIDs, paracetamol, diclofenac-paracetamol)
Study: 12519847
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist long protocol (group A; n = 45)
Study: 12519847
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol commencing recombinant FSH on cycle day 2 (group B; n = 48)
Study: 12519847
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol commencing recombinant FSH on cycle day 5 (group C; n = 49)
Study: 1353803
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine nasal spray (0.5 mg per shot)
Study: 12225705
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine nasal spray
Study: 1353803
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine nasal spray and Placebo nasal spray
Study: 6501724
Drug: Nifedipine (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (34 +/- 22 mg)
Study: 6501724
Drug: Hydralazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (10 +/- 5 mg)
Study: 31182176
Drug: Psychotropic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medication prescribed on discharge (including neuroleptics, antidepressants, anxiolytics)
Study: 29575951
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training protocol (3 times weekly, 60 minutes per session for 6 months)
Study: 26595966
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with PLIESF and therapeutic physical exercises
Study: 24213914
Drug: Structured Treatment
Normalized name: Lipid,structured (From Sunflower Oil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Treatment Interruptions (STIs) consisting of five STIs of 1, 1, 2, 2, and 3 months, respectively, separated by four periods of 3-month therapy
Study: 24213914
Drug: Standard continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard continuous treatment
Study: 18065829
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation combined with a single bout of resistance exercise (PO + EX)
Study: 18065829
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation alone (PO)
Study: 16758243
Drug: Reboxetine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (8 mg/day; n=20)
Study: 16758243
Drug: Mirtazapine (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (45 mg/day; n=20)
Study: 12766690
Drug: Cognitive-processing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-processing therapy
Study: 12766690
Drug: Delayed-treatment waiting-list
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-treatment waiting-list condition
Study: 9050084
Drug: Pimozide (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide (8 mg)
Study: 9050084
Drug: d-Amphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine (10 and 20 mg)
Study: 9050084
Drug: Pimozide (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide (8 mg) + d-Amphetamine (10 and 20 mg)
Study: 1315651
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (800 mg)
Study: 6421918
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of sodium cromoglycate (SCG)
Study: 24591191
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of D. farinae drops for 48 weeks
Study: 22112683
Drug: Prior warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior warfarin only
Study: 22112683
Drug: Prior ASA
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior ASA and warfarin
Study: 22112683
Drug: No prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prior therapy
Study: 17975496
Drug: Temsirolimus 250
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 250 mg
Study: 17975496
Drug: Overall (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (both doses)
Study: 15777522
Drug: Moxifloxacin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (1000 mg total dose, single blind, one day oral provocation test)
Study: 2695999
Drug: Personalized prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized prescription
Study: 2695999
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard prescription)
Study: 405408
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 4% solution instilled into each eye 4 times daily
Study: 28107729
Drug: Recombinant LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant LH (rLH) supplementation (75 IU daily from day 7 of FSH stimulation to the day of HCG trigger)
Study: 23608774
Drug: Levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25% 1 ml/kg plus sufentanil 0.5 μg/kg (Group LS)
Study: 23608774
Drug: Levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25% 1 ml/kg only (Group L)
Study: 12005088
Drug: q48h dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: q48h dosing schedule (5.0 or 4.5 mg/kg/dose q48h)
Study: 12005088
Drug: q24h dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: q24h dosing schedule (2.5 or 3.0 mg/kg/dose q24h)
Study: 12005088
Drug: q48h dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: q48h dosing schedule
Study: 12005088
Drug: q24h dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: q24h dosing schedule
Study: 2550335
Drug: Kabi 2165
Normalized name: immunoglobulin G, human Injectable Solution [Kabiglobulin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kabi 2165 (low-molecular-weight heparin) 2 X 2,500 anti-Xa units s.c.